

Exhibit F

Exhibit F

BMS/OTN Price Dispersion: Excluding Sales to Federal Entities
 % of Net Revenue at Net Transaction Prices
Oncology Products

Blenoxane													
	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP	0.0%	0.0%	0.0%	0.0%	0.8%	2.8%	31.3%	69.6%	70.4%	5.7%	0.0%	15.7%	
50 - <75% of WLP	0.5%	1.2%	1.5%	5.8%	59.9%	80.6%	78.8%	60.8%	27.2%	25.0%	24.6%	2.2%	64.0%
75 - <90% of WLP	0.0%			13.9%	22.7%	9.6%	3.0%	1.2%	0.8%	0.0%	5.2%	3.2%	8.8%
90 - <95% of WLP	0.9%	0.0%	2.7%	14.3%	2.2%	0.2%				2.9%	4.3%	0.6%	
>95% of WLP	98.6%	98.8%	95.9%	65.9%	15.2%	8.9%	15.5%	6.7%	2.4%	4.6%	61.5%	90.4%	10.9%
Cytoxan													
	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP	49.5%	59.2%	53.5%	66.7%	83.2%	91.1%	94.9%	82.1%	93.9%	71.0%	73.5%		73.5%
50 - <75% of WLP	33.1%	11.3%	3.2%	1.4%	0.7%	0.6%	-0.1%	-0.1%	-0.1%		4.4%		4.4%
75 - <90% of WLP	1.4%	0.9%	0.7%	0.1%	0.0%	0.0%	0.0%		-0.3%		0.3%		0.3%
90 - <95% of WLP	0.3%	0.0%	0.0%	0.0%	0.0%		0.0%			0.0%	0.0%		0.0%
>95% of WLP	15.7%	28.6%	42.5%	31.7%	16.0%	8.3%	5.2%	18.0%	6.5%	29.0%	21.8%		21.8%
Cytoxan Tablets													
	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP	0.0%	0.0%	0.0%	0.0%	0.0%		0.0%	0.0%	0.0%		0.0%	0.0%	0.0%
50 - <75% of WLP	0.3%	0.8%	0.9%	0.7%	0.0%	0.0%	0.0%	0.2%	2.1%	24.6%	1.8%	0.4%	11.4%
75 - <90% of WLP	0.0%	0.0%	0.0%	0.1%		0.1%	0.0%	0.0%		0.1%	0.0%	0.0%	0.0%
90 - <95% of WLP	0.0%	0.0%	2.1%	0.0%	0.0%	0.1%	26.8%	9.2%		0.0%	4.4%	5.1%	0.0%
>95% of WLP	99.7%	99.2%	96.9%	99.2%	99.9%	99.8%	73.1%	90.6%	97.9%	75.4%	93.8%	94.5%	88.5%
Paraplatin													
	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
50 - <75% of WLP	0.1%	0.6%	0.6%	0.5%	0.0%	0.1%	0.1%	0.0%	0.0%	0.0%	0.1%	0.1%	0.1%
75 - <90% of WLP	0.8%	0.0%	0.0%	0.2%	0.2%	0.0%	0.0%		0.2%	11.0%	1.8%	1.8%	
90 - <95% of WLP	0.0%	0.0%	4.0%	3.4%	5.5%	0.1%	0.1%	2.0%	5.2%	5.6%	3.1%	3.1%	
>95% of WLP	99.1%	99.4%	95.3%	95.9%	94.3%	99.8%	99.8%	98.0%	94.5%	83.4%	94.9%	94.9%	
Taxol													
	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP							0.0%		0.0%	46.7%	2.1%	0.0%	10.3%
50 - <75% of WLP							0.0%		5.2%	24.4%	1.9%	0.0%	9.5%
75 - <90% of WLP						0.0%	0.1%	0.2%	27.7%	28.3%	5.7%	0.1%	27.8%
90 - <95% of WLP								4.9%	28.4%	0.1%	5.8%	1.7%	22.1%
>95% of WLP					100.0%	99.9%	99.8%	95.1%	38.7%	0.5%	84.6%	98.2%	30.3%
VePesid													
	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP	0.0%	0.0%	12.0%	85.1%	85.4%	94.5%	91.9%	44.2%	85.2%	88.9%	26.8%	0.0%	46.9%
50 - <75% of WLP	0.8%	34.1%	68.7%	9.2%	2.0%	0.5%	0.3%	0.0%	0.0%	0.1%	32.0%	26.1%	36.5%
75 - <90% of WLP	19.4%	46.8%	9.9%	1.6%	0.0%	-0.9%	-0.5%	-0.4%	-0.7%	0.1%	20.2%	40.2%	5.2%
90 - <95% of WLP	1.9%	3.0%	1.3%	0.2%	0.2%	0.4%		0.1%			1.6%	2.7%	0.8%
>95% of WLP	77.8%	16.1%	8.1%	3.8%	12.4%	5.5%	8.3%	56.2%	15.5%	11.0%	19.3%	31.0%	10.6%
VePesid Capsules													
	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%		0.0%		0.1%	0.0%	0.0%	0.1%
50 - <75% of WLP	0.6%	0.9%	0.8%	1.1%	0.0%	0.1%	0.1%	0.0%	0.0%	0.7%	0.4%	0.4%	0.7%
75 - <90% of WLP		0.5%	1.4%	0.6%	0.0%	0.3%	0.2%	0.1%	0.0%		0.3%	0.3%	0.0%
90 - <95% of WLP	0.1%	0.0%	0.4%	0.8%	0.3%	0.1%	13.6%	20.7%	0.0%	7.2%	4.6%	4.4%	7.2%
>95% of WLP	99.3%	98.6%	97.5%	97.5%	99.7%	99.5%	86.1%	79.2%	100.0%	92.0%	94.7%	94.8%	92.0%
All Oncology Products													
	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP	2.3%	1.6%	4.0%	8.6%	3.2%	1.1%	0.8%	0.9%	1.3%	11.4%	2.7%	0.0%	20.2%
50 - <75% of WLP	2.0%	10.1%	14.1%	1.9%	2.8%	1.3%	1.3%	0.6%	2.6%	5.6%	2.8%	0.5%	17.6%
75 - <90% of WLP	3.7%	12.7%	2.1%	1.8%	1.1%	0.2%	0.2%	0.0%	12.8%	14.0%	4.1%	1.6%	19.9%
90 - <95% of WLP	0.7%	0.8%	2.8%	3.8%	3.3%	0.0%	0.8%	4.1%	15.6%	4.3%	4.3%	2.7%	14.9%
>95% of WLP	91.3%	74.8%	77.1%	83.9%	89.5%	97.4%	96.9%	94.4%	67.8%	64.8%	86.2%	95.2%	27.4%

Exhibit F**BMS/OTN Price Dispersion: Excluding Sales to Federal Entities**
% of Net Revenue at Net Transaction Prices**Primary Care/Virology Products****Avapro**

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP						0.0%	0.0%				0.0%	0.0%	
50 - <75% of WLP						0.0%	0.0%	0.0%	0.0%	0.1%	0.0%	0.0%	
75 - <90% of WLP						0.0%	0.1%	0.0%	0.1%	6.5%	1.8%	1.8%	
90 - <95% of WLP						0.0%	0.0%	0.0%	0.6%	3.8%	1.1%	1.1%	
>95% of WLP						100.0%	100.0%	99.9%	100.0%	99.3%	89.7%	97.1%	97.1%

Buspar

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP	0.0%	0.0%	0.0%	0.0%		0.0%	0.0%	0.0%	-0.1%		0.0%	0.0%	
50 - <75% of WLP	0.2%	0.4%	0.5%	0.4%	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.1%	0.1%	0.1%
75 - <90% of WLP	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.2%	0.1%	0.0%	0.0%	0.0%	0.0%
90 - <95% of WLP	0.2%	0.0%	0.1%	0.1%	0.2%	4.5%	0.4%	6.1%	0.3%	0.2%	2.0%	2.0%	0.2%
>95% of WLP	99.5%	99.5%	99.4%	99.5%	99.7%	95.4%	99.6%	93.8%	99.7%	99.7%	97.8%	97.8%	99.7%

Cefzil Suspension

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP	0.0%	0.0%	0.0%	0.0%	0.0%	-0.2%	0.0%	0.0%	0.0%		0.0%	0.0%	
50 - <75% of WLP	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	
75 - <90% of WLP	0.0%	0.0%	0.1%	0.1%	0.1%	0.1%	0.1%	0.0%	0.0%	15.1%	0.8%	0.8%	
90 - <95% of WLP	0.0%	0.3%	0.4%	0.2%	0.2%	0.3%	14.5%	0.9%	-4.4%	2.1%	2.1%		
>95% of WLP	100.0%	99.9%	99.5%	99.4%	99.7%	99.9%	99.6%	85.4%	99.0%	89.3%	97.1%	97.1%	

Cefzil Tablets

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP	0.0%	0.0%	0.0%	0.0%	0.0%	-0.2%	0.0%	0.0%	0.0%		0.0%	0.0%	
50 - <75% of WLP	0.0%	0.0%	0.0%	0.1%	0.2%	0.1%	0.0%	0.0%	0.0%	0.0%	0.1%	0.1%	
75 - <90% of WLP	0.0%	0.0%	0.1%	0.2%	0.2%	0.1%	0.1%	0.2%	0.0%	1.5%	0.2%	0.2%	
90 - <95% of WLP	0.0%	0.2%	0.2%	0.1%	0.0%	8.1%	22.6%	1.1%	-0.6%	4.4%	4.4%		
>95% of WLP	100.0%	100.0%	99.7%	99.7%	99.6%	99.8%	91.8%	77.1%	98.9%	99.1%	95.4%	95.4%	

Coumadin

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP						0.2%	3.5%	8.8%	12.0%	1.3%	4.1%		4.1%
50 - <75% of WLP						5.1%	2.6%	1.5%	2.6%	0.0%	2.4%		2.4%
75 - <90% of WLP						0.0%	0.0%	1.5%	0.0%	1.1%	0.5%		0.5%
90 - <95% of WLP						0.0%	2.0%	1.3%	5.7%	2.1%	1.9%		1.9%
>95% of WLP						94.7%	91.8%	86.9%	79.6%	95.6%	91.2%		91.2%

Glucophage

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP						0.0%	0.0%	0.0%	0.0%	0.2%	0.0%	0.0%	
50 - <75% of WLP						0.0%	0.0%	0.0%	0.0%	0.2%	0.0%	0.0%	
75 - <90% of WLP						0.5%	0.6%	0.1%	0.6%	0.2%	13.4%	4.0%	4.3%
90 - <95% of WLP						0.2%	5.2%	0.4%	13.9%	12.7%	15.7%	3.5%	10.9%
>95% of WLP						99.5%	99.2%	94.7%	99.0%	85.5%	87.0%	70.9%	84.7%

Glucophage XR

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP											0.0%	0.0%	0.0%
50 - <75% of WLP											0.0%	0.0%	0.0%
75 - <90% of WLP											10.5%	4.2%	4.2%
90 - <95% of WLP											99.4%	4.8%	10.7%
>95% of WLP											0.6%	95.2%	85.0%

Glucovance

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP											0.0%	0.0%	0.0%
50 - <75% of WLP											0.0%	0.0%	0.0%
75 - <90% of WLP											11.7%	1.4%	7.2%
90 - <95% of WLP											77.1%	0.8%	21.3%
>95% of WLP											11.1%	97.8%	71.5%

Exhibit F

BMS/OTN Price Dispersion: Excluding Sales to Federal Entities

% of Net Revenue at Net Transaction Prices

Monopril

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP			2.1%	1.6%	0.2%	0.3%	0.3%	0.2%	0.2%	0.2%	0.4%	0.4%	0.4%
50 - <75% of WLP		0.8%	0.6%	0.5%	0.1%	0.1%	0.1%	0.0%	0.0%	0.0%	0.1%	0.1%	0.1%
75 - <90% of WLP		0.0%	0.0%	0.0%	0.0%	2.2%	0.1%	0.0%	0.0%	27.7%	3.0%	3.0%	
90 - <95% of WLP		0.1%	0.3%	0.0%	0.1%	0.0%	0.1%	0.0%	0.2%	7.6%	0.9%	0.9%	
>95% of WLP	100.0%	99.2%	97.3%	97.8%	99.3%	97.4%	99.4%	99.7%	99.5%	64.5%	95.6%	95.6%	

Monopril HCT

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP								0.0%	0.1%	0.0%	0.1%	0.1%	0.1%
50 - <75% of WLP								0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
75 - <90% of WLP							0.0%		16.3%	6.5%	6.5%		
90 - <95% of WLP								6.4%		2.6%	2.6%		
>95% of WLP								100.0%	99.9%	77.3%	90.9%	90.9%	

Plavix

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP							0.0%	0.0%			0.0%	0.0%	0.0%
50 - <75% of WLP						0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
75 - <90% of WLP					0.0%	0.0%	0.0%	0.0%	0.0%	6.2%	2.3%	2.3%	
90 - <95% of WLP						5.2%	0.0%	14.5%	6.3%	6.3%			
>95% of WLP					100.0%	100.0%	94.8%	100.0%	79.3%	91.4%	91.4%		

Serzone

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP					0.0%	0.0%	0.0%	0.7%	0.0%	0.0%	0.1%	0.1%	
50 - <75% of WLP			0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	
75 - <90% of WLP			0.1%	0.3%	0.4%	0.1%	0.4%	0.0%	0.4%	37.7%	3.2%	3.2%	
90 - <95% of WLP				1.2%	5.0%	4.4%	1.2%	8.3%	16.4%	10.0%	7.6%	7.6%	
>95% of WLP		99.8%	98.4%	94.7%	95.5%	98.4%	91.0%	83.2%	52.3%	89.0%	89.0%		

Tequin

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP								0.0%	0.0%	0.0%	0.0%	0.0%	
50 - <75% of WLP			0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	
75 - <90% of WLP			0.1%	0.3%	0.4%	0.1%	0.4%	0.0%	0.4%	37.7%	3.2%	3.2%	
90 - <95% of WLP				1.2%	5.0%	4.4%	1.2%	8.3%	16.4%	10.0%	7.6%	7.6%	
>95% of WLP		99.8%	98.4%	94.7%	95.5%	98.4%	91.0%	83.2%	52.3%	89.0%	89.0%		

Videx EC

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP							0.0%	0.0%	0.0%	0.0%	0.2%	0.2%	
50 - <75% of WLP							0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	
75 - <90% of WLP							11.4%	3.0%	6.5%	5.2%	5.2%		
90 - <95% of WLP					97.8%	6.9%	6.6%	18.7%	14.6%	14.6%			
>95% of WLP					2.2%	81.7%	90.5%	74.9%	80.2%	80.2%			

All Primary Care/Virology Products

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP	0.0%	0.0%	0.1%	0.2%	0.0%	0.0%	0.4%	0.5%	0.3%	0.1%	0.3%	0.0%	4.0%
50 - <75% of WLP	0.1%	0.3%	0.3%	0.2%	0.0%	0.7%	0.3%	0.1%	0.1%	0.0%	0.2%	0.0%	2.4%
75 - <90% of WLP	0.0%	0.0%	0.1%	0.2%	0.1%	0.4%	0.2%	0.7%	4.8%	8.9%	2.6%	2.7%	0.5%
90 - <95% of WLP	0.1%	0.0%	0.1%	0.3%	2.4%	1.4%	6.1%	11.1%	7.3%	10.6%	6.6%	6.9%	1.8%
>95% of WLP	99.7%	99.7%	99.4%	99.2%	97.4%	97.5%	93.0%	87.6%	87.5%	80.4%	90.4%	90.3%	91.3%

All Products

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP	0.6%	0.6%	1.5%	2.3%	0.8%	0.4%	0.5%	0.6%	0.5%	2.2%	0.8%	0.0%	10.7%
50 - <75% of WLP	0.6%	4.1%	5.0%	0.6%	0.7%	0.9%	0.6%	0.2%	0.5%	1.1%	0.8%	0.2%	8.7%
75 - <90% of WLP	1.0%	4.9%	0.8%	0.6%	0.4%	0.3%	0.2%	0.5%	6.1%	9.9%	2.9%	2.5%	8.6%
90 - <95% of WLP	0.3%	0.3%	1.1%	1.2%	2.6%	1.0%	4.6%	9.4%	8.6%	9.4%	6.1%	6.0%	7.3%
>95% of WLP	97.4%	90.0%	91.7%	95.3%	95.4%	97.5%	94.1%	89.3%	84.3%	77.4%	89.4%	91.4%	64.7%

Exhibit F

BMS/OTN Price Dispersion: Excluding Sales to Federal Entities

% of Net Revenue at Net Transaction Prices

Sources:

Notes:

See Exhibit D for an explanation of the underlying price calculations and the shares shown above. Post-generic shares are calculated from years in which a generic was available for the entire year. Coumadin figures prior to 2002 do not exclude sales to federal government entities.